ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics


ACADIA Pharmaceuticals Inc. (ACAD): $19.84

-0.01 (-0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACAD POWR Grades

  • Quality is the dimension where ACAD ranks best; there it ranks ahead of 94.55% of US stocks.
  • ACAD's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • ACAD's current lowest rank is in the Sentiment metric (where it is better than 28.98% of US stocks).

ACAD Stock Summary

  • For ACAD, its debt to operating expenses ratio is greater than that reported by just 13.4% of US equities we're observing.
  • With a price/sales ratio of 6.28, ACADIA PHARMACEUTICALS INC has a higher such ratio than 81.07% of stocks in our set.
  • ACAD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 21.24% of US stocks.
  • Stocks that are quantitatively similar to ACAD, based on their financial statements, market capitalization, and price volatility, are OVID, SPRO, FKWL, VYNE, and GANX.
  • Visit ACAD's SEC page to see the company's official filings. To visit the company's web site, go to www.acadia-pharm.com.

ACAD Valuation Summary

  • In comparison to the median Healthcare stock, ACAD's price/sales ratio is 15.69% higher, now standing at 5.9.
  • Over the past 227 months, ACAD's price/sales ratio has gone down 11.6.

Below are key valuation metrics over time for ACAD.

Stock Date P/S P/B P/E EV/EBIT
ACAD 2023-01-30 5.9 7.0 -13.8 -13.4
ACAD 2023-01-27 5.9 7.1 -13.8 -13.5
ACAD 2023-01-26 5.9 7.1 -13.9 -13.5
ACAD 2023-01-25 5.9 7.1 -13.9 -13.6
ACAD 2023-01-24 6.0 7.2 -14.2 -13.8
ACAD 2023-01-23 6.0 7.3 -14.2 -13.9

ACAD Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at 43.32%.
  • The 4 year revenue growth rate now stands at 1022.82%.
  • The 2 year cash and equivalents growth rate now stands at 17.82%.
ACAD's revenue has moved up $172,427,000 over the prior 33 months.

The table below shows ACAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 511.503 -113.301 -217.344
2022-06-30 512.401 -129.638 -204.618
2022-03-31 493.059 -141.84 -214.478
2021-12-31 484.145 -125.66 -167.87
2021-09-30 474.394 -130.028 -191.536
2021-06-30 463.359 -135.757 -261.739

ACAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACAD has a Quality Grade of C, ranking ahead of 66.5% of graded US stocks.
  • ACAD's asset turnover comes in at 0.606 -- ranking 51st of 682 Pharmaceutical Products stocks.
  • AKBA, PBYI, and DRRX are the stocks whose asset turnover ratios are most correlated with ACAD.

The table below shows ACAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.606 0.980 -0.702
2021-03-31 0.593 0.979 -0.724
2020-12-31 0.573 0.977 -0.744
2020-09-30 0.543 0.974 -0.652
2020-06-30 0.515 0.972 -0.541
2020-03-31 0.531 0.969 -0.585

ACAD Price Target

For more insight on analysts targets of ACAD, see our ACAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.53 Average Broker Recommendation 1.83 (Hold)

ACAD Stock Price Chart Interactive Chart >

Price chart for ACAD

ACAD Price/Volume Stats

Current price $19.84 52-week high $28.06
Prev. close $19.85 52-week low $12.24
Day low $19.74 Volume 443,186
Day high $19.97 Avg. volume 1,210,649
50-day MA $16.84 Dividend yield N/A
200-day MA $16.50 Market Cap 3.21B

ACADIA Pharmaceuticals Inc. (ACAD) Company Bio


Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.


ACAD Latest News Stream


Event/Time News Detail
Loading, please wait...

ACAD Latest Social Stream


Loading social stream, please wait...

View Full ACAD Social Stream

Latest ACAD News From Around the Web

Below are the latest news stories about ACADIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

Acadia Pharmaceuticals: What''s Ahead In 2023

ACADIA Pharmaceuticals had one major disappointment in 2022 but has some potential new drug approvals on the horizon. Click here to read my analysis of ACAD.

Seeking Alpha | January 16, 2023

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned retirement was announced last year. “We

Business Wire | January 9, 2023

Acadia Pharmaceuticals bulls will need to be patient for now

Acadia Pharmaceuticals (ACAD) bulls will need to be patient for now as the company''s charts simply aren''t showing sustained strength, writes technical analyst Bruce Kamich….ACAD

The Street RealMoney | January 3, 2023

Opening Bell Analysts Research Calls for Tuesday, January 3

This report was sent to Briefing.com subscribers earlier today. Research calls posted earlier this morning are available here. Upgrades: > ACADIA Pharmaceuticals (ACAD) upgraded to Buy from Neutral at Guggenheim; tgt $22 > Allegion (ALLE) upgraded to Buy from Hold at Vertical Research; tgt $128 > Becton Dickinson (BDX) upgraded to Buy from Neutral at […]

24/7 Wall street | January 3, 2023

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups. NUPLAZID is the only medication approved by the U.S.

Wallstreet:Online | January 3, 2023

Read More 'ACAD' Stories Here

ACAD Price Returns

1-mo 14.68%
3-mo 32.62%
6-mo 26.05%
1-year -21.61%
3-year -52.39%
5-year -30.02%
YTD 24.62%
2022 -31.79%
2021 -56.34%
2020 24.96%
2019 164.56%
2018 -46.30%

Continue Researching ACAD

Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:

Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7104 seconds.